Adjuvant treatments for gastric cancer: from practice guidelines to clinical practice.
Fiche publication
Date publication
janvier 2014
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BEDENNE Laurent, Dr BOUVIER Anne-Marie, Dr JOUVE Jean-Louis, Pr LEPAGE Côme
Tous les auteurs :
Bouvier AM, Crehange G, Azelie C, Cheynel N, Jouve JL, Bedenne L, Faivre J, Lepage C, Maingon P
Lien Pubmed
Résumé
BACKGROUND: For gastric cancers, the benefits of adjuvant radiochemotherapy and of perioperative chemotherapy have been demonstrated since 2001 and 2006 respectively. The aim of this study was to evaluate the diffusion of adjuvant treatments in a French population. METHODS: 334 incident gastric cancers UICC Stage IB, II, III or IVM0 resected for cure and recorded in the Burgundy digestive cancer registry were retrospectively included. Patients were classified as having received an effective adjuvant treatment if they had been treated by adjuvant radiochemotherapy since 2001 or perioperative chemotherapy since 2006. RESULTS: The proportion of patients treated with an effective adjuvant treatment increased from 21.8% (2001-2005) to 40.1% (2006-2009). Patients treated in 2006-2009 were twice as likely to receive effective adjuvant treatment as those treated during the period 2001-2005. During the 2004-2009 period, 62.4% of cases were presented in a multidisciplinary team meeting. These patients were almost three times more likely to receive effective adjuvant treatment than patients excluded from multidisciplinary team consultation. Age was a significant factor, independent of comorbidities. CONCLUSION: Administration of adjuvant treatment is still far from being considered a reference regimen in routine practice for R0 resected gastric cancer. The increase in multidisciplinary team meetings should improve the situation.
Référence
Dig Liver Dis. 2014 Jan;46(1):72-5